By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it presented new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to ...
O'Connell projected, "We expect to read out ALTITUDE-AD late this year, inclusive of key clinical efficacy and safety measures." He indicated that results from this study would inform development ...
Acumen Pharmaceuticals will present new findings on sabirnetug at AAIC 2025, focusing on Alzheimer's disease treatments and trial efficiency. Acumen Pharmaceuticals, Inc. announced that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results